Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects

References

• Faxon DP, Williams DO. Interventional cardiology: current status and future directions in coronary disease and valvular heart disease. Circulation. 2016 Jun 21;133(25):2697–2711.
   PubMed Web of Science ®Google Scholar
• Cao D, Chandiramani R, Chiarito M, et al. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J. 2021 Jan 21;42(4):339–351. DOI:10.1093/eurheartj/ehaa824
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011 Jun 14;123(23):2736–2747. DOI:10.1161/CIRCULATIONAHA.110.009449
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011 Jul 5;8(9):502–512.
   PubMed Web of Science ®Google Scholar
• Libby P, Pasterkamp G, Crea F, et al. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019 Jan 4;124(1):150–160. DOI:10.1161/CIRCRESAHA.118.311098
   PubMed Web of Science ®Google Scholar
• Vergallo R, Crea F. Atherosclerotic plaque healing. N Engl J Med. 2020 Aug 27;383(9):846–857.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010 Jan;31(1):17–28.
   PubMed Web of Science ®Google Scholar
• Del Brutto VJ, Chaturvedi S, Diener HC, et al. Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease: jACC scientific expert panel. J Am Coll Cardiol. 2019 Aug 13;74(6):786–803. DOI:10.1016/j.jacc.2019.06.039
   PubMed Web of Science ®Google Scholar
• Hess CN, Bonaca MP. Contemporary review of antithrombotic therapy in peripheral artery disease. Circ Cardiovasc Interv. 2020 Oct;13(10):e009584.
   PubMed Web of Science ®Google Scholar
• Awtry EH, Loscalzo J. Aspirin. Circulation. 2000 Mar 14;101(10):1206–1218.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849–1860.
   PubMed Web of Science ®Google Scholar
• Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529–1539.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1519–1528. DOI:10.1056/NEJMoa1803955
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1509–1518. DOI:10.1056/NEJMoa1805819
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018 Oct 18;379(16):1499–1508. DOI:10.1056/NEJMoa1800722
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 Sep 22;392(10152):1036–1046. DOI:10.1016/S0140-6736(18)31924-X
   PubMed Web of Science ®Google Scholar
• Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019 Jan 22;321(3):277–287.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 [2019 Sep 10];140(11):e596–646.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv. 2015 Mar;8(3):e002301.
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, O’Connor SA, Silvain J, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012 Dec 19;308(23):2507–2516. DOI:10.1001/jama.2012.50788
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411–2420. DOI:10.1001/jama.288.19.2411
   PubMed Web of Science ®Google Scholar
• Widimsky P, Motovská Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008 Jun;29(12):1495–1503.
   PubMed Web of Science ®Google Scholar
• Jurga J, Szummer KE, Lewinter C, et al. Pretreatment with P2Y12 inhibitors in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a report from the swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2021 Nov;14(11):e010849.
   PubMed Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;79(2):e21–129. 2022 Jan 18. DOI:10.1016/j.jacc.2021.09.006.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494–502.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013 Sep 12;369(11):999–1010. DOI:10.1056/NEJMoa1308075
   PubMed Web of Science ®Google Scholar
• Tarantini G, Mojoli M, Varbella F, et al. Timing of oral P2Y(12) inhibitor administration in patients with non-ST-Segment elevation acute coronary syndrome. J Am Coll Cardiol. 2020 Nov 24;76(21):2450–2459. DOI:10.1016/j.jacc.2020.08.053
   PubMed Web of Science ®Google Scholar
• Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019 Oct 17;381(16):1524–1534. DOI:10.1056/NEJMoa1908973
   PubMed Web of Science ®Google Scholar
• Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol. 2012 Apr;101(4):305–312.
   PubMed Web of Science ®Google Scholar
• Ducci K, Grotti S, Falsini G, et al. Comparison of pre-hospital 600 mg or 900 mg vs. peri-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial. Int J Cardiol. 2013 Oct 12;168(5):4814–4816. DOI:10.1016/j.ijcard.2013.07.012
   PubMed Web of Science ®Google Scholar
• Montalescot G, van ‘t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014 Sep 11;371(11):1016–1027. DOI:10.1056/NEJMoa1407024
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015. DOI:10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–1057. DOI:10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10;361(24):2318–2329. DOI:10.1056/NEJMoa0908628
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10;361(24):2330–2341. DOI:10.1056/NEJMoa0908629
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4;368(14):1303–1313. DOI:10.1056/NEJMoa1300815
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14;382(9909):1981–1992. DOI:10.1016/S0140-6736(13)61615-3
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42(14):1289–1367. 2021 Apr 7. DOI:10.1093/eurheartj/ehaa575.
   Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–177. 2018 Jan 7. DOI:10.1093/eurheartj/ehx393.
   Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022 Feb;19(2):117–132.
   PubMed Web of Science ®Google Scholar
• Zwart B, Parker WAE, Storey RF. New antithrombotic drugs in acute coronary syndrome. J Clin Med. 2020 Jun 30;9(7):2059.
   PubMed Web of Science ®Google Scholar
• Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016 Oct 25;68(17):1851–1864. DOI:10.1016/j.jacc.2016.07.760
   PubMed Web of Science ®Google Scholar
• Pelliccia F, Pasceri V, Marazzi G, et al. Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: the RE-SCORE multicentre prospective registry. Eur J Prev Cardiol. 2021 Oct 13;28(12):e36–38. DOI:10.1177/2047487320937846
   PubMed Web of Science ®Google Scholar
• Généreux P, Giustino G, Redfors B, et al. Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. Int J Cardiol. 2018 Oct 1;268:61–67. DOI:10.1016/j.ijcard.2018.03.103.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar 5;360(10):961–972. DOI:10.1056/NEJMoa0804626
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016 May 17;67(19):2224–2234. DOI:10.1016/j.jacc.2016.02.064
   PubMed Web of Science ®Google Scholar
• Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010 May 4;55(18):1923–1932. DOI:10.1016/j.jacc.2010.02.005
   PubMed Web of Science ®Google Scholar
• Wykrzykowska JJ, Garg S, Onuma Y, et al. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the ‘All-Comers’ LEADERS trial. Circ Cardiovasc Interv. 2011 Feb 1;4(1):47–56. DOI:10.1161/CIRCINTERVENTIONS.110.958389
   PubMed Web of Science ®Google Scholar
• Singh M, Lennon RJ, Holmes DR Jr., et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002 Aug 7;40(3):387–393. DOI:10.1016/S0735-1097(02)01980-0
   PubMed Web of Science ®Google Scholar
• Wu C, Hannan EL, Walford G, et al. A risk score to predict in-hospital mortality for percutaneous coronary interventions. J Am Coll Cardiol. 2006 Feb 7;47(3):654–660. DOI:10.1016/j.jacc.2005.09.071
   PubMed Web of Science ®Google Scholar
• Pocock S, Bueno H, Licour M, et al. Predictors of one-year mortality at hospital discharge after acute coronary syndromes: a new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns in acute CORonary syndrome patients) study. Eur Heart J Acute Cardiovasc Care. 2015 Dec;4(6):509–517.
   PubMedGoogle Scholar
• Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013 Feb 23;381(9867):639–650. DOI:10.1016/S0140-6736(13)60108-7
   PubMed Web of Science ®Google Scholar
• Takahashi K, Serruys PW, Fuster V, et al. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. Lancet. 2020 Oct 31;396(10260):1399–1412. DOI:10.1016/S0140-6736(20)32114-0
   PubMed Web of Science ®Google Scholar
• Pyxaras SA, Mangiacapra F, Wijns W, et al. ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):1067–1073. DOI:10.1002/ccd.25360
   PubMed Web of Science ®Google Scholar
• Protty M, Sharp ASP, Gallagher S, et al. Defining percutaneous coronary intervention complexity and risk: an analysis of the United Kingdom BCIS database 2006-2016. JACC: Cardiovasc Interv. 2022 Jan 10;15(1):39–49. DOI:10.1016/j.jcin.2021.09.039
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019 Jul 16;140(3):240–261. DOI:10.1161/CIRCULATIONAHA.119.040167
   PubMed Web of Science ®Google Scholar
• Cao D, Mehran R, Dangas G, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol. 2020 Jun 2;75(21):2711–2722. DOI:10.1016/j.jacc.2020.03.070
   PubMed Web of Science ®Google Scholar
• Urban P, Gregson J, Owen R, et al. Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-High bleeding risk trade-off model. JAMA Cardiol. 2021 Apr 1;6(4):410–419. DOI:10.1001/jamacardio.2020.6814
   PubMed Web of Science ®Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016 Apr 26;315(16):1735–1749. DOI:10.1001/jama.2016.3775
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017 Mar 11;389(10073):1025–1034. DOI:10.1016/S0140-6736(17)30397-5
   PubMed Web of Science ®Google Scholar
• Costa F, Van Klaveren D, Feres F, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019 Feb 26;73(7):741–754. DOI:10.1016/j.jacc.2018.11.048
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013 Oct;73(15):1681–1709.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577–2585. DOI:10.1161/CIRCULATIONAHA.109.912550
   PubMed Web of Science ®Google Scholar
• Erlinge D, Ten Berg J, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012 Nov 13;60(20):2032–2040. DOI:10.1016/j.jacc.2012.08.964
   PubMed Web of Science ®Google Scholar
• Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013 Aug 13;62(7):577–583. DOI:10.1016/j.jacc.2013.05.023
   PubMedGoogle Scholar
• Savonitto S, Ferri LA, Piatti L, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018 Jun 5;137(23):2435–2445. DOI:10.1161/CIRCULATIONAHA.117.032180
   PubMed Web of Science ®Google Scholar
• Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 Oct 4;367(14):1297–1309. DOI:10.1056/NEJMoa1205512
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost. 2012 Dec;108(6):1031–1036.
   PubMed Web of Science ®Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020 Apr 25;395(10233):1374–1381. DOI:10.1016/S0140-6736(20)30325-1
   PubMed Web of Science ®Google Scholar
• Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation. 2016 Nov 22;134(21):1603–1612. DOI:10.1161/CIRCULATIONAHA.116.024823
   PubMed Web of Science ®Google Scholar
• Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020 Jul 14;142(2):150–160. DOI:10.1161/CIRCULATIONAHA.120.046786
   PubMed Web of Science ®Google Scholar
• Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC: Cardiovasc Interv. 2013 Dec;6(12):1267–1274.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155–2166. DOI:10.1056/NEJMoa1409312
   PubMed Web of Science ®Google Scholar
• Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015 May 26;65(20):2211–2221. DOI:10.1016/j.jacc.2015.03.003
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19):1791–1800. DOI:10.1056/NEJMoa1500857
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019 Oct 3;381(14):1309–1320. DOI:10.1056/NEJMoa1908077
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28;394(10204):1169–1180. DOI:10.1016/S0140-6736(19)31887-2
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020 Apr;17(4):242–257.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9–19. DOI:10.1056/NEJMoa1112277
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017 Oct 5;377(14):1319–1330. DOI:10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14;38(11):804–810. DOI:10.1093/eurheartj/ehw525
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015 Nov 19;373(21):2038–2047. DOI:10.1056/NEJMoa1503943
   PubMed Web of Science ®Google Scholar
• Sorrentino S, Claessen BE, Chandiramani R, et al. Long-term safety and efficacy of durable polymer cobalt-chromium everolimus-eluting stents in patients at high bleeding risk: a patient-level stratified analysis from four postapproval studies. Circulation. 2020 Mar 17;141(11):891–901. DOI:10.1161/CIRCULATIONAHA.119.041619
   PubMed Web of Science ®Google Scholar
• Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020 Mar 26;382(13):1208–1218. DOI:10.1056/NEJMoa1910021
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021 Oct 28;385(18):1643–1655. DOI:10.1056/NEJMoa2108749
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015 Jan;12(1):30–47.
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011 Mar;9(3):552–561.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018 Aug;15(8):480–496.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30;381(9872):1107–1115. DOI:10.1016/S0140-6736(12)62177-1
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 Sep 15;392(10151):940–949. DOI:10.1016/S0140-6736(18)31858-0
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019 Nov 21;381(21):2032–2042. DOI:10.1056/NEJMoa1908419
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2020 May 19;75(19):2403–2413. DOI:10.1016/j.jacc.2020.03.008
   PubMed Web of Science ®Google Scholar
• Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: tWILIGHT-ACS. Eur Heart J. 2020 Oct 1;41(37):3533–3545. DOI:10.1093/eurheartj/ehaa670
   PubMed Web of Science ®Google Scholar
• Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020 May 19;75(19):2414–2424. DOI:10.1016/j.jacc.2020.03.011
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020 Jun 16;323(23):2407–2416. DOI:10.1001/jama.2020.7580
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019 Jun 25;321(24):2428–2437. DOI:10.1001/jama.2019.8146
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019 Jun 25;321(24):2414–2427. DOI:10.1001/jama.2019.8145
   PubMed Web of Science ®Google Scholar
• Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022 Apr 1;7(4):407–417. DOI:10.1001/jamacardio.2021.5244
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. Bmj. 2021 Jun 16;373:p. n1332.
   Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC: Cardiovasc Interv. 2019 Aug 26;12(16):1521–1537. DOI:10.1016/j.jcin.2019.03.034
   PubMed Web of Science ®Google Scholar
• Michelson AD, Bhatt DL. How I use laboratory monitoring of antiplatelet therapy. Blood. 2017 Aug 10;130(6):713–721.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26;61(8):872–879. DOI:10.1016/j.jacc.2012.11.040
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015 Jul 14;36(27):1762–1771. DOI:10.1093/eurheartj/ehv104
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010 Feb 24;303(8):754–762. DOI:10.1001/jama.2010.181
   PubMed Web of Science ®Google Scholar
• Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010 Jul 20;56(4):317–318. DOI:10.1016/j.jacc.2010.03.048
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16;305(11):1097–1105. DOI:10.1001/jama.2011.290
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) study. J Am Coll Cardiol. 2012 Jun 12;59(24):2159–2164. DOI:10.1016/j.jacc.2012.02.026
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016 Oct 22;388(10055):2015–2022. DOI:10.1016/S0140-6736(16)31323-X
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017 Oct 14;390(10104):1747–1757. DOI:10.1016/S0140-6736(17)32155-4
   PubMed Web of Science ®Google Scholar
• Zheng YY, Wu TT, Yang Y, et al. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211–221. DOI:10.1093/ehjcvp/pvz059
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet. 2017 Oct 14;390(10104):1718–1720.
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019 Oct 24;381(17):1621–1631. DOI:10.1056/NEJMoa1907096
   PubMed Web of Science ®Google Scholar
• Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020 Aug 25;324(8):761–771. DOI:10.1001/jama.2020.12443
   PubMed Web of Science ®Google Scholar
• Moliterno DJ, Smyth SS, Abdel-Latif A. CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary interventions: one size rarely fits all. JAMA. 2020 Aug 25;324(8):747–749.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC: Cardiovasc Interv. 2020 Mar 9;13(5):606–617. DOI:10.1016/j.jcin.2020.01.226
   PubMed Web of Science ®Google Scholar
• Bittl JA. The ABCD-GENE score for clopidogrel response: not just another cardiac risk Model. JACC: Cardiovasc Interv. 2020 Mar 9;13(5):618–620.
   PubMed Web of Science ®Google Scholar
• Imam H, Nguyen TH, De Caterina R, et al. Impaired adenylate cyclase signaling in acute myocardial ischemia: impact on effectiveness of P2Y(12) receptor antagonists. Thromb Res. 2019 Sep;181:92–98.
   PubMed Web of Science ®Google Scholar
• Hurst NL, Nooney VB, Chirkov YY, et al. Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. Thromb Res. 2015 Aug;136(2):308–314.
   PubMed Web of Science ®Google Scholar
• Nooney VB, Hurst NL, De Caterina R, et al. Does high on-treatment platelet aggregability reflect poor individual response to clopidogrel? Thromb Res. 2020 Dec;196:510–515.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017 Nov 1;38(41):3070–3078. DOI:10.1093/eurheartj/ehx175
   PubMed Web of Science ®Google Scholar
• Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020 Oct 10;396(10257):1079–1089. DOI:10.1016/S0140-6736(20)31791-8
   PubMed Web of Science ®Google Scholar
• Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021 Oct 9;398(10308):1305–1316. DOI:10.1016/S0140-6736(21)01445-8
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kimura K, Kimura T, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J. 2020 Apr 24;84(5):831–865. DOI:10.1253/circj.CJ-19-1109
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;41(3):407–477. 2020 Jan 14. DOI:10.1093/eurheartj/ehz425.
   Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509–1524. DOI:10.1056/NEJMoa1817083
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Oct 12;394(10206):1335–1343. DOI:10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar
• Lopes RD, Hong H, Harskamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019 Aug 1;4(8):747–755. DOI:10.1001/jamacardio.2019.1880
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update. Circulation. 2021 Feb 9;143(6):583–596. DOI:10.1161/CIRCULATIONAHA.120.050438
   PubMed Web of Science ®Google Scholar
• Jacobsen AP, Raber I, McCarthy CP, et al. Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: still Sacrosanct or is reappraisal warranted? Circulation. 2020 Oct 20;142(16):1579–1590. DOI:10.1161/CIRCULATIONAHA.120.045695
   PubMed Web of Science ®Google Scholar
• Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021 Jun 26;397(10293):2487–2496. DOI:10.1016/S0140-6736(21)01063-1
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127(3):377–385. DOI:10.1161/CIRCULATIONAHA.112.117283
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Lanza F, et al. Pharmacokinetic/Pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. J Thromb Thrombolysis. 2019 Nov;48(4):554–562.
   PubMed Web of Science ®Google Scholar
• Sinnaeve P, Fahrni G, Schelfaut D, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol. 2020 May 26;75(20):2588–2597. DOI:10.1016/j.jacc.2020.03.059
   PubMed Web of Science ®Google Scholar
• Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein VI, in patients undergoing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled ISAR-PLASTER phase 2 trial. JAMA Cardiol. 2021 Jul 1;6(7):753–761. DOI:10.1001/jamacardio.2021.0475
   PubMed Web of Science ®Google Scholar
• Li J, Vootukuri S, Shang Y, et al. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2321–2329.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Desai UR. Factor xIa inhibitors: a review of the patent literature. Expert Opin Ther Pat. 2016;26(3):323–345.
   PubMed Web of Science ®Google Scholar
• Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400–1411.
   PubMed Web of Science ®Google Scholar
• Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022 Oct 18;146(16):1196–1206. DOI:10.1161/CIRCULATIONAHA.122.061612
   PubMed Web of Science ®Google Scholar
• Kalinin DV. Factor XII(a) inhibitors: a review of the patent literature. Expert Opin Ther Pat. 2021 Dec;31(12):1155–1176.
   PubMed Web of Science ®Google Scholar